纤维蛋白凝块或骨髓刺激技术辅助修复水平状半月板撕裂的临床结果：一项2年随访的回顾性研究
简介
本研究回顾性分析了52例接受关节镜修复的症状性半月板水平撕裂患者，分别采用骨髓刺激（BMV组）或纤维蛋白凝块（FC组）进行生物增强。两组术后KOOS和Lysholm评分均显著改善（P<0.01），但2年随访时组间无显著差异（KOOS P=0.13，Lysholm P=0.17）。MRI评估显示，FC组和BMV组III级高信号率分别为34.48%和30.44%…
英文摘要
BACKGROUND: Biologic augmentation techniques play a key role in overcoming the inherently reduced healing ability of horizontal cleavage meniscus tears (HCTs). The purpose of this study was to evaluate and compare the clinical results and the healing rate of HCT arthroscopic repair, augmented with bone marrow venting or fibrin clot. METHODS: A total of 52 patients who underwent arthroscopic repair for symptomatic meniscal HCT were included in this retrospective study. All patients received biologic augmentation in the form of either bone marrow venting (BMV group) or fibrin clot (FC group). The two groups were compared in terms of clinical symptoms and meniscal healing. Clinical evaluation was performed using the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Lysholm score. Meniscal healing was assessed both clinically and via magnetic resonance imaging (MRI). RESULTS: Both groups demonstrated significant improvement in KOOS and Lysholm scores postoperatively (P < 0.01). No significant differences were found between the FC and BMV groups in the 2-year postoperative KOOS (P = 0.13) or Lysholm scores (P = 0.17). Meniscus healing assessment on 2-year postoperative MRI revealed an increased rate of grade III hyperintensity (34.48% FC group; 30.44% BMV group). Overall clinical failure was 9.6% and did not differ between the two groups (P = 0.64). CONCLUSION: Both BMV and FC augmentation methods of arthroscopic repair for meniscal HCT provide good clinical results with low clinical failure rates. Neither technique demonstrated superiority in terms of clinical results or healing rates.